A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118

Status:
Unknown status

Trial end date:
2013-07-01

Target enrollment:

Participant gender:

Subjects with a clinical diagnosis of plaque psoriasis with 10% to 20% of body surface area affected will be enrolled in the study.

Phase 1/Phase 2

Dow Pharmaceutical Sciences